

# **TB CARE II**

# **Ethics of TB Prevention, Care and Control:**

An Assessment Tool for National Tuberculosis Programmes

# January 2015

#### **DISCLAIMER**

This study is made possible by the support of the American people through the United States Agency for International Development (USAID). The information provided in this guide is the sole responsibility of University Research Co., LLC and its partner the Global TB Institute, and do not necessarily reflect the views of USAID or the United States Government

# Acknowledgements

TB CARE II is funded by United States Agency for International Development (USAID) under Cooperative Agreement Number AID-OAA-A-10-00021. The project team includes prime recipient, University Research Co., LLC (URC), and sub-recipient organizations Jhpiego, Partners in Health, Project HOPE along with the Canadian Lung Association; Clinical and Laboratory Standards Institute; Dartmouth Medical School: The Section of Infectious Disease and International Health; Euro Health Group; MASS Design Group; and the Global Tuberculosis Institute at Rutgers, The State University of New Jersey. This document was produced for review by the United States Agency for International Development. It was prepared by Global Tuberculosis Institute at Rutgers, The State University of New Jersey, and was authored by Rajita Bhavaraju, MPH with major contributions to the pilot testing of the ethics tool by Dadivo Jose Litsecuane Combane, MA (Consultant, Lecturer, Eduardo Mondlane University), Orlando Alberto Govo, MSc (Consultant, Lecturer at Eduardo Mondlane University), Simiao Antonio Mahumana, MSc (Country Representative, Project HOPE Mozambique), Ivan Manhica, MPH (National Coordinator, NTP Mozambique), Steve Neri (Country Representative, Project HOPE Namibia), and Dalleen Witbooi Consultant).

# Ethics of TB Prevention, Care and Control: An Assessment Tool for National TB Programmes

# **Background**

In 2010, the World Health Organisation (WHO) released *Guidance on Ethics of Tuberculosis Prevention, Care and Control*. This guidance is meant to address all dilemmas related to the rights of TB patients, the community, TB programmes, and health care workers in the management of TB patients.

The purpose of this tool is for programmes to assess themselves on topics covered in the WHO guidelines. The tool will assist programmes in identifying potential strengths and gaps in the ethical treatment of TB patients.

As part of the pilot testing process, responders noted the benefits of using this tool. They indicated that the tool is an important refresher for the key components of TB care which can improve patient care, protect the community and families, and change the environment for health care workers. However, this is based on full use of the tool, recognizing its findings and a commitment to making changes to existing practices.

# **Description**

This tool contains guided questions about TB control activities on various levels in a TB programme. There are no correct or incorrect responses. This instrument can be used to identify ethical issues and help to make decisions on how to address them with current resources.

# **Process**

There are several ways to complete this tool. The questions cover various topics and one person in a program or at the patient-care level may not know how to answer all of the questions. Should one choose to have individuals answer the questions, it may be helpful to designate certain questions for persons with specific roles (e.g., treatment questions for physicians and/or nurses). As roles differ in every region and country, these have not been pre-designated in this document. Each programme should make this decision based on their organization and structure.

An additional approach would be to have a team of people complete the tool together. In order to complete this tool using this approach, a group of personnel should be assembled who understand the following circumstances in a particular country or setting:

- Drug procurement
- Access to care
- Resource availability
- Support for vulnerable populations
- Diagnostic procedures
- Contact tracing
- Research
- Legal interventions

- Provider practices
- Adherence enhancing interventions

Personnel may not be all National TB Programme (NTP) staff but representatives from district level programmes.

The form to be completed is provided *here* (This document may be in PDF but a separate link to a Word document is needed) in Microsoft Word® and can be customized. This revision may include:

- Changing terms that are not understandable in the context in which this tool is being used
- Deleting questions which are not pertinent to the person(s) completing the tool; one may create different documents for each type of individual participating the assessment process
- Adding explanations to questions where required. Explanations, however, should be defining and not leading the respondent to a certain answer

The tool completion is expected to take several hours for a group to complete and about 30-60 minutes for an individual to complete. It will require participants to discuss current practices in the country with relation to the care of persons with TB. Additional documentation may be required to cover the above listed topics including the legal regulations for health care. If the tool is completed as a group, an unbiased facilitator and note taker should be available to guide t and document the process.

The tool is meant as a way for programmes or facilities to assess and discuss the ethical practices within their organization, with the goal of improvement. It is not intended as mechanism for disciplining or penalizing staff. When the tool is used in a group, all staff members should be encouraged to be comfortable sharing their observations and opinions openly.

Detailed instructions are available for several questions that require further explanations. After using the assessment tool, refer to the supplement at the end of the tool on how to interpret and use the information.

#### Planning, Monitoring and Evaluation

After the assessment of ethical practices, it is important to summarize the results. This can be done in the document itself noting frequencies of response and a list of open-ended responses. One may also separate responses based on who stated them (i.e., by profession, district, level of care, etc.). This latter method can provide some context for certain responses.

This response summary should be considered to address changes in practice and policy. An ethics strategic plan may be considered with realistic timelines, specific and measureable objectives and designated tasks to achieve ethical patient care. The plan can be revisited when feasible to assess if accomplished objective are being sustained.

# Ethics of TB Prevention, Care and Control: An Assessment Tool for National TB Programmes

Use this instrument to answer questions about TB control activities in your programme. There are no correct or incorrect responses. This instrument can be used to identify ethics issues in your programme and help to make decision on how to address them with current resources.

	QUESTION		RESPONSE	
	me):			
Job location (city and facility				
Jot	title:			
	(1)			
Na	me (optional):			

QUESTION	RESPONSE
ACCESS TO CARE	
1. Are anti-TB drugs provided free of charge to <b>all</b> TB patients under	□Yes (go to 2)
all circumstances?	□No (go to 1a)
	□I do not know the answer to this (go to 2)
1a. Under what circumstances do patients have to pay for	☐Treatment for drug-resistant disease
anti-TB drugs (check all that	□Private sector care
apply)?	□Patient goes direct to pharmacy
	□Treatment for latent TB infection
	☐Treatment for exposure to infectious TB
	□Other (specify)
Comments on any of the responses:	1

2. Are <u>all</u> aspects of TB care provided free of charge under <u>all</u>	□Yes (go to 3)
circumstances?	☐ No - Not all services, all the time (go to 2a)
	□I do not know the answer to this (go to 3)
2a. Under what circumstances and reasons do patient need to pay for TB care (select all that apply)?	□X-ray – Circumstance:
	□Sputum collection – Circumstance:
	□Sputum smear microscopy –
	Circumstance:
	□Drug susceptibility testing - Circumstance:
	☐Receipt of personal respiratory protection (mask)—Circumstance:
	□ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □
	☐Care for related conditions (e.g., HIV) –  Circumstance:
	□Other – Circumstance:
Comments on any of the responses:	
3. Do patients with drug-resistant TB have the same access to treatment as patients without drug-resistance?	☐ Yes (go to 4) ☐ No - Not all services, all the time (go to 3a)

	□I do not know the answer to this (go to 4)	
3a. Do patients with drug- resistant TB have access to	□Free drugs	
the following care? (select all	□Personal respiratory protection (masks)	
that apply)	□Care for other related conditions (e.g., HIV)	
	□Directly observed therapy	
	□Other	
Comments on any of the responses:		
4. Does the national TB programme	□Yes	
(NTP) receive any support (e.g., money, TB drugs) from	(specify source(s))	
international source(s)?	□No (provide reason)	
	□I do not know the answer to this	
Comments on any of the responses:		
5. Does the NTP have a process to		
be sure the quality of TB drugs is	□Yes	
good?	(specify, e.g., received through GDF) (go to 6)	
	$\square$ No (go to 5a)	
	☐I do not know the answer to this (go to 6)	
5a. If quality of drugs is not assured, how do providers decide regimens to use and with what frequency?		
5a1. Providers use the	☐Most of the time	
drugs provided as recommended,	□Sometimes	
regardless of quality	□Rarely	
5a2. Providers do <u>not</u> treat a patient if there are no quality assured	☐Most of the time	
	□Sometimes	
drugs	□Rarely	
Comments on any of the responses:		

6. Do patients travel a great distance to a facility for TB services including:	
a. Medical examination	☐Most of the time
	□Sometimes
	□Rarely
	□Not at all
	□I do not know the answer to this
b. Directly Observed Therapy (DOT)	☐Most of the time
Directly observed therapy is the	□Sometimes
process by which a trained health care worker watches and	□Rarely
documents the ingestion of anti- TB medications in a patient.	□Not at all
12 mearcanons av a panena	□I do not know the answer to this
c. Sputum collection	☐Most of the time
	□Sometimes
	□Rarely
	□Not at all
	□I do not know the answer to this
d. X-ray	☐Most of the time
	□Sometimes
	□Rarely
	□Not at all
	$\Box$ I do not know the answer to this
e. Care for related conditions (e.g., HIV)	☐Most of the time
(0.5., 111 + )	□Sometimes
	□Rarely

	□Not at all
	□I do not know the answer to this
Other (specify)	
State which services above are circumstances:	in the same facility in most cases and under what
Comments on any of the responses:	
7 Is access to TP sarvious different for	or different types of patients (see list below)?
a. Local minorities	☐ Most of the time
	□Sometimes
	□Rarely
	□Not at all
	☐I do not know the answer to this
b. Homeless persons	☐Most of the time
	□Sometimes
	□Rarely
	□Not at all
	□I do not know the answer to this
c. Migrants/refugees	☐Most of the time
	□Sometimes
	□Rarely
	□Not at all
	□I do not know the answer to this
d. Prison inmates	☐Most of the time
	□Sometimes
	□Rarely
	□Not at all

	□I do not know the answer to this
e. Rural populations	☐Most of the time
	□Sometimes
	□Rarely
	□Not at all
	□I do not know the answer to this
f. Substance abusers	☐Most of the time
	□Sometimes
	□Rarely
	□Not at all
	$\Box$ I do not know the answer to this
g. Women/children	☐Most of the time
	□Sometimes
	□Rarely
	□Not at all
	□I do not know the answer to this
h. Poor	☐Most of the time
	□Sometimes
	□Rarely
	□Not at all
	□I do not know the answer to this
i. Other (specify)	☐Most of the time
	□Sometimes
	□Rarely
	□Not at all
Comments on any of the responses:	

8. Are there community-based clinics?	☐Yes (See comment area below)	
cinics:	□No	
	□I do not know the answer to this	
9. Are there private (sole practice) providers?	□Yes (See comment area below)	
providers:	□No	
	□I do not know the answer to this	
Comments on any of the responses regarding community care (questions 8 and 9) (e.g., adherence to patient's rights and respect, scheduling appointments, waiting areas, waiting time, access to care, etc.):		
PATIENT CENTRED CARE		
10. Do patient support groups exist?	□Many	
A patient support group is formal	□Some	
meeting or a way for patients to meet with other patients or a counselor	□Few	
about issues related to their care, such as depression.	□None	
such as acpression.	□I do not know the answer to this	
Comments:		
	for vulnerable populations? You may provide a services are available to each group:	
a. Local minorities	☐Many	
	□Some	
	□Few	
	□None	
	□I do not know the answer to this	
Comments:		
b. Homeless persons	□Many	

	□Some
	□Few
	□None
	□I do not know the answer to this
Comments:	
c. Migrants/refugees	□Many
	□Some
	□Few
	□None
	□I do not know the answer to this
Comments:	
d. Indigenous persons/tribe members	□Many
P • 13 • 13 • 11 • 11 • 11 • 11 • 11 • 1	□Some
	□Few
	□None
	□I do not know the answer to this
Comments:	
e. Prison inmates	□Many
	□Some
	□Few
	□None
	□I do not know the answer to this
Comments:	
f. Rural populations	□Many

	□Some
	□Few
	□None
	☐I do not know the answer to this
Comments:	
g. Substance abusers	□Many
	□Some
	□Few
	□None
	□I do not know the answer to this
Comments:	
h. Women/children	□Many
	□Some
	□Few
	□None
	□I do not know the answer to this
Comments:	
i. Mine workers	□Many
	□Some
	□Few
	□None
	☐I do not know the answer to this
Comments:	
12. Are there trained, community health care workers who provide	□Many

services for TB patients?  Community health care workers	□Some
are not medical or nursing	□Few
professionals but persons with no formal health care education.	□None
	□I do not know the answer to this
Comments:	<u>L</u>
INFORMATION, COUNSELING, A	AND CONSENT
-	iformed consent on the TB testing and treatment isks and benefits of a procedure or process. It may be gwith the patient.
a. TB Testing:	☐Most of the time
	□Sometimes
	□Rarely
	□Not at all
	□I do not know the answer to this
b. TB Treatment:	☐Most of the time
	□Sometimes
	□Rarely
	□Not at all
	□I do not know the answer to this
c. Personal infection control:	☐Most of the time
condor.	□Sometimes
	□Rarely
	□Not at all
	□I do not know the answer to this
d. Contact tracing:	☐Most of the time
	□Sometimes
	□Rarely

	□Not at all
	□I do not know the answer to this
e. Drug susceptibility	☐Most of the time
testing:	□Sometimes
	□Rarely
	□Not at all
	☐I do not know the answer to this
f. HIV testing	☐Most of the time
	□Sometimes
	□Rarely
	□Not at all
	☐I do not know the answer to this
Comments on any of the responses:	
14. Is contact tracing conducted by health care workers?	☐Most of the time (go to 14a)
Contact tracing is a means of finding	□Sometimes (go to 14a)
persons exposed to an infectious case of TB in order to bring them for	□Rarely (go to 14b)
medical examination to treat new cases and prevent new cases via	□Never (go to 14b)
treatment for latent TB infection and	□I do not know the answer to this
preventive therapy.  14a. If contact tracing is	□Yes
performed, is the patient's identity always kept	□No
confidential?	
	☐ Identity is revealed if there is no other option to
	identify contacts
	☐I do not know the answer to this
14b. If contact tracing is not performed by health care	☐Most of the time
workers, are patients asked or	□Sometimes
encouraged to notify their contacts of their TB disease?	□Rarely

	□Never
	□I do not know the answer to this
Comments on any of the responses:	
<u>ADHERENCE</u>	
15. Is directly observed therapy (DOT) provided?  Directly observed therapy is the process by which a trained health care worker watches and documents the ingestion of anti-TB medications in a patient.	☐Universally used. If so, for what duration during treatment or when is it no longer used?
	□It is only used in certain circumstances (check all that apply): □Drug resistant cases
	☐HIV-infected cases
	☐Urban settings
	□Rural settings
	□Children
	□Patients with high likelihood of non-adherence (specify types)
	□It is not used
16. Are <b>enablers</b> present for patient	□ I do not know the answer to this
care? An enabler is a resource which makes a patient's ability to adhere to treatment easier. An example is a bus ticket or free transportation to the clinic.	☐Most of the time ☐Sometimes ☐Rarely
	□Never (go to 17)
•	□I do not know the answer to this (go to 17)
16a. Are enablers only used for certain types of patients?	☐Yes (specify what type(s)):
	□No
	□I do not know the answer to this
17. Are <b>incentives</b> offered to patients for adhering to treatment	☐Most of the time

or other medical care?  An incentive is a reward for	□Sometimes
completing agreed upon medical	□Rarely
management issues like completion of a treatment course	□Never (go to 18)
or getting an x-ray.	□I do not know the answer to this (go to 18)
15	answer to this (go to 16)
17a. Are incentives only used for certain types of patients?	☐Yes (specify what type(s)):
••	□No
	☐I do not know the answer to this
18. Are the following in place to enhan	nce adherence?
	g a task or treatment as advised by health care
provider (e.g., taking a full course	of treatment).
Written agreement at the initiation of treatment	□Yes
	□No
	□I do not know the answer to this
b. Visit or contact by letter or telephone/mobile phone if patient is not adherent	□Yes
	□No
	□I do not know the answer to this
c. Visit or contact by a health	□Yes
care worker if patient is not adherent	□No
	□I do not know the answer to this
d. Change in treatment provision	□Yes
method (e.g., change in time of DOT, provision of other necessary medical services, etc.)	□No
	□I do not know the answer to this
19. Will the programme treat patients who are not likely to be adherent?  If worker's time or medications will likely be used for a patient	□Yes
	□No
	□I do not know the answer to this
who may not take medications as	
prescribed, is this patient not started on treatment?	
20. Is there a facility or plan for patients who cannot be cured but	□Yes

remain infectious?	□No
	□I do not know the answer to this
Comments on any of the responses for	the questions on adherence:
	G AND TREATMENT OF RESISTANT
DISEASE	
21. Is drug susceptibility testing provided or offered to all	☐Most of the time
patients regardless of the	□Sometimes
availability of 2 <sup>nd</sup> or 3 <sup>rd</sup> line drugs?	□Rarely
	□No, the provider does not know
	☐I do not know the answer to this
22. Are providers able to make treatment decisions when drug	☐Most of the time
susceptibility testing is not	□Sometimes
available?  Do physicians know how to treat	□Rarely
a patient when they are not clear what drugs will work to cure the	□No, the provider does not know
patient?	□I do not know the answer to this
Comments on any of the responses:	
HEALTH CARE WORKERS' RIGH	TS AND ORLICATIONS
23. Are the following adequate for health care workers:	
a. Infection control (personal):	☐Most of the time
Personal infection control	□Sometimes
refers to the availability of respirators and masks,	□Rarely
etc.	□Not at all
	□I do not know the answer to this

b. Infection control (facility):	☐Most of the time
Personal infection control	□Sometimes
refers to the airborne infection isolation rooms,	□Rarely
ultraviolet germicidal irradiation (UVGI), etc.	□Not at all
irradiation (0 v 01), etc.	□I do not know the answer to this
c. Medical supplies:	☐Most of the time
	□Sometimes
	□Rarely
	□Not at all
	☐I do not know the answer to this
d. Training:	☐Most of the time
	□Sometimes
	□Rarely
	□Not at all
	□I do not know the answer to this
e. Equipment:	☐Most of the time
	□Sometimes
	□Rarely
	□Not at all
	☐I do not know the answer to this
f. Infrastructure:	☐Most of the time
	□Sometimes
	□Rarely
	□Not at all
	□I do not know the answer to this
g. Drug supply:	☐Most of the time
	□Sometimes

	□Rarely
	□Not at all
	□I do not know the answer to this
Comments on any of the responses:	
24. Are the following provided to heal	th care workers:
a. Health information	☐Most of the time
(written or verbal) on the risks and benefits	□Sometimes
of caring for TB patients:	□Rarely
1	□Never
	□I do not know the answer to this
b. Training on caring for TB patients:	☐Most of the time
1 b patients.	□Sometimes
	□Rarely
	□Never
	□I do not know the answer to this
c. Access to TB screening and	☐Most of the time
diagnosis:	□Sometimes
	□Rarely
	□Never
	□I do not know the answer to this
d. Access to treatment for TB, if needed:	☐Most of the time
	□Sometimes
	□Rarely
	□Never
	□I do not know the answer to this
e. Clear description of roles and	☐Most of the time

responsibilities:	□Sometimes
	□Rarely
	□Never
	□I do not know the answer to this
f. Appropriate	☐Most of the time
compensation:  Compensation refers to	□Sometimes
salary, holidays, time away from work if sick.	□Rarely
	□Never
	□I do not know the answer to this
g. Ability to approach a supervisor to address	☐Most of the time
unsafe or inadequate	□Sometimes
working conditions:	□Rarely
	□Never
	□I do not know the answer to this
Comments on any of the responses:	
ISOLATIONAND LEGAL INTERY	<u>VENTIONS</u>
25. Are infectious patients asked to be separated (isolated) from household members?	☐Most of the time
	□Sometimes
	□Rarely
	□Never
	□I do not know the answer to this
26. Are there laws, regulations, and/or policies establishing procedures and conditions of involuntary (against the patient's will) isolation?	□Yes (go to 26a)
	□No (go to 26b)
	□I do not know the answer to this
26a. At the beginning of	□Yes
treatment, is a patient told that he or she can be isolated or	

detained is not adherent?	□No – The patient is not told even though this is the
	policy
	☐ No - The patient is not told because our program
	does not have an isolation or detention policy
	□I do not know the answer to this
26b. What is done if a patient:	
*	ment, and all reasonable measures to ensure
adherence have been attemp	
(e.g., wear a mask, stay awa	to treatment but is unable to institute infection control v from other people) in the
home:	y from other people) in the
iii. Is probably not contagious b	
infectiousness?	
27. If you answered ves to question 21:	if involuntary isolation or detention is implemented,
is there language in the related law,	
a. Strict necessity	□Yes
(isolation or detention	
should only be used if absolutely needed):	□No
absolutety needed).	☐I do not know the answer to this
b. Least restriction and	□Yes
intrusion (if a patient	
is isolated or detained it should be done with	□No
the least possible	☐I do not know the answer to this
inconvenience and	
done humanly):	
c. Not arbitrary,	□Yes
unreasonable, or discriminatory (if a	□No
patient is isolated or	
detained there should	☐I do not know the answer to this
be an appropriate	
reason, consistent with	
a policy based on the	
non-adherence):  Comments on any of the responses:	
comments of any of the responses.	
RESEARCH	

28. Is there ongoing <b>TB</b> research in country related to:	
a. Medications:	□Yes
	□No
	□I do not know the answer to this
b. Vaccines	□Yes
	□No
	□I do not know the answer to this
c. Treatment regimens	S □Yes
	□No
	□I do not know the answer to this
d. Social and structura determinants of	ll □Yes
disease:	□No
	□I do not know the answer to this No
e. Infection control:	□Yes
	□No
	□I do not know the answer to this
f. Adherence strategie	es:
	□No
	□I do not know the answer to this
g. Drug delivery mechanisms:	□Yes
	□No
	□I do not know the answer to this
h. Social/behavioral interventions:	□Yes
	□No
	□I do not know the answer to this
i. Epidemiology:	□Yes

		□No
		☐I do not know the answer to this
j.	Other (specify)	
(if you ans	of any kind is present swered yes to at least n questions 28, please elow):	
a.	Are local investigators present (for	□Yes
	internationally	□No
	sponsored research only)?	□Not applicable
		□I do not know the answer to this
b.	Are participants kept informed of the	□Yes
	research findings and	□No
	how the finding are being used?	□I do not know the answer to this
c.	Is the research beneficial to the	□Yes
	populations in which it	□No
	is carried out?	□I do not know the answer to this
d.	Will research results be locally adaptable?	□Yes
	be rocally adaptable.	□No
		□I do not know the answer to this
e.	Is an ethics committee/institutiona	□Yes
	l review board	□No
	involved in the assessment of human	□I do not know the answer to this
f.	subjects research? Has consent been	
1.	obtained from persons	□Yes
	who participate in	□No
	research?	□I do not know the answer to this
g.	Is there an agreement among all researchers	□Yes

about access to medical care and	□No
treatment of persons being studied?	□I do not know the answer to this
h. Is there a policy on specimen collection	□Yes
and/or storage?	□No
	□I do not know the answer to this
Comments on any of the responses:	

# **Resolution to the Responses for the Tool**

After responding to the questions, please review the information below from the WHO document, *Guidance on ethics of tuberculosis prevention, care and control* (http://whqlibdoc.who.int/publications/2010/9789241500531\_eng.pdf).

The information provided is a brief summary on each question, which addresses the consensus by the authoring committee on the appropriate ethical stance that should be taken. The information below in conjunction with gaps identified in the tool, can indicate where further policy changes, internal and external resource allocation, and research may be needed to meet the identified needs on ethics. The complete *Guidance on ethics of tuberculosis prevention, care and control* document will be useful to more fully explore and understand gaps identified through use of the Ethics Assessment Tool.

For more specific information on interventions and examples of the described ethical practices, consult the references at the end of the Guidance document.

# **Access to Care**

#### Questions 1 and 1a

Anti-TB drugs should be available free of charge to all TB patients. When TB drugs are not free, patients who are unable to afford them may not get treatment and may remain sick and infectious. This both affects the uncured patient and fails to stop transmission in the community.

# Questions 2 and 2a

All aspects of TB care should be free of charge. This includes diagnostic care and drug susceptibility testing. Treatment of active TB disease as well as preventive therapy should also be free. TB patients should also have free access to related care such as HIV services since some other infections and medical conditions may affect the course of TB and its treatment.

#### Questions 3 and 3a

Patients with drug resistant disease should be given the same treatment and care as patients with susceptible disease. This includes access to drugs, infection control, directly observed treatment, and supportive community programmes. Training should be present to ensure that health care workers are providing appropriate medication regimens to patients not only with drug resistant disease, but with susceptible disease to avoid secondary resistance.

#### Question 4

The international community has an obligation to provide support to resource-poor countries when universal access to care, as outlined above, cannot be provided. Sources of drugs and other services should be sought.

# Question 5 and 5a

The National Tuberculosis Programme should ensure that anti-TB drugs are not substandard and can be supplied with regularity; failing to do so can harm individual patients and contribute to the development and spread of drug resistant strains. If drug supply and quality are a concern, it is the NTP's role to inform local providers of not only the problems, but steps to take in treating patients under these conditions.

#### Question 6, 8, 9, 12

If treatment and care are not easily accessible to TB patients, strategies should be developed to make them accessible. Care can be provided in local communities, on an outpatient basis, using trained local health care and community workers. Care can include a medical examination, directly observed therapy, sputum collection, x-rays, and oversight for other related conditions.

#### **Patient Centered Care**

#### Question 7 and 11

All patients should have access to TB care services regardless of their vulnerabilities. Tailored interventions can be devised to this effect that focus on making access easier. These include the use of local health care providers and setting-based (e.g., prison) services.

# Question 10

Patients should be encouraged to come together to in a supportive environment to discuss their medical and psychological concerns. These groups can also work within the community together to resolve challenges related to TB care.

# Question 12

Community workers play an important role in treatment and symptom assessment of patients. They should be adequately trained and compensated for their time and work.

#### Information, Counseling, and Consent

# Question 13

TB patients should be provided all information about any procedures or treatments related to their TB diagnosis. This both educates patients and serves to assist them in making decisions about their medical care and adherence. While choices about treatment may be limited, as TB is a communicable disease, assistance should be provided in understanding the importance of medical care. Information should be provided with culture and language specificity in mind.

# Question 14, 14a, and 14b

Whether contact tracing is required by local officials, patients should be encouraged to report their TB diagnosis to their close contacts to prevent additional spread of disease. When a health care workers or the local TB programme is involved in contact notification, all efforts should be made to keep the patient's identification confidential. If the patient is not cooperative in this process, his or her name *may* need to be disclosed in order to discover potential contacts. However, this should be considered as a last resort option, and used only after all reasonable efforts to gain the patients cooperation have failed.

#### Adherence

#### Question 15

Directly observed therapy (DOT) is a way of supporting patients through their regimen. By assisting in successful completion of treatment, DOT can help to prevent the spread of TB. It should be done when possible, at the convenience of the patient by ensuring a mutually agreed upon time schedule, choice of health care worker, and location for administration. All of this is done with confidentiality and privacy in mind as well as availability of resources.

#### Question 16

Enablers are a way to allow patients to receive care particularly when access is difficult or other medical conditions may be interfering in care. Examples of enablers include transportation vouchers/tickets or nutritional supplements. Enablers should be provided when needed and can be obtained through outside funding and collaborations.

# Question 17

Incentives should be provided, when appropriate, in exchange for treatment adherence or completion (e.g., doll for a child). They should be culturally appropriate and should not be provided if doing so would be considered insulting.

#### Question 18

If a patient is non-adherent to treatment, all efforts should be made to provide an opportunity for the patient to receive services. Patients should be informed at treatment initiation about the importance of adherence as well as the consequences of non-adherence. If non-adherence occurs, health care workers should find out what may be causing the problem and try and remedy it together with the patient. If attempts at the latter are not successful, then gradual methods of warnings such as letters and visits to the patient's home should occur.

# Question 19

It is difficult to predict adherence in a patient. Therefore, providers are obligated to discuss the importance of adherence at the start of treatment and then provide adherence enhancing interventions (e.g., education, enablers, incentives) throughout treatment if adherence is a concern. Care of any patient should not be denied on the basis of adherence; in the situation where the patient refuses treatment, legal interventions may be taken as a last resort measure.

# Question 20

TB programmes and providers must provide care to keep the incurable patient comfortable. If the patient is infectious, infection control mechanisms (including isolation in a mutually agreed upon environment) should be in place so that the patient does not infect others, including health care workers.

# **Drug Susceptibility Testing and Treatment of Drug Resistant Patients**

#### Question 21

If a programme is unable to treat a drug resistant patient, susceptibility testing should still be initiated, although patients should be provided information on risks and benefits of testing and specifically asked if they are willing to consent even though treatment is not available to them. The results of such testing can assist providers in deciding which regimens to use and not use, guide the patient in making decisions about personal infection control practices, and allow the patient to understand why his or her care may not be successful. Use of diagnostic testing without the ability to treat patients should only be a temporary measure and programmes should develop a timeline and strategy for offering treatment for drug-resistant TB.

# Question 22

If a provider is unable to successfully treat a patient based on drug susceptibility results and/or drug availability, he or she should make decisions how to make the patient comfortable and non-infectious to others. If drug susceptibility testing is not available, treatment decisions can be made based on local epidemiology and patient-specific factors. This decision making process should occur in a multidisciplinary fashion, not just looking at medical concerns.

# **Health Care Worker Rights and Obligations**

#### Ouestions 23 and 24

Health care workers are obligated to take care of all TB patients. However, in doing so, health care workers take great risks in becoming infected themselves and having the caregiving process become an overwhelming responsibility. TB programmes are obligated to provide to health care workers: adequate personal and facility-based infection control, medical supplies, training, equipment, infrastructure, and drug supply. Workers should be informed of all risks they are taking, be given a clear job description, and be afforded the same care as TB patients related to access to care should they also become infected.

If health care workers do not have appropriate environments to provide care in, they should have a process by which they can appeal to local government or the management of their facility of work for better conditions.

# **Isolation and Legal Interventions**

#### Question 25

If a patient is considered infectious, isolation should be done with minimal inconvenience to the patient as well as assuring his or her quality of life. This includes separating a patient from his family with careful consideration; if the family members have already been exposed and evaluated as part of a contact tracing process, then it may not be necessary to isolate the patient from them.

#### Question 25, 26, and 27

Treatment for TB should be accompanied by shared information and education and mutual decision-making between the patient and health care provider. If patients are not adherent after all reasonable attempts have been made, detention may be used as a last resort measure. In this case, the welfare of the community is more important. However, involuntary isolation or detention should be done humanely and be based on established procedures which are applied to all persons, not just to those vulnerable populations for whom there may be no one to advocate on their behalf.

#### Research

#### Question 28

Research on the various aspects of TB care should be conducted within a country and at a local level on all aspects of TB care including: drugs, vaccines, treatment regimens, social determinants of disease, infection control, adherence, drug delivery, socio-behavioral interventions, epidemiology and others. It is acceptable to solicit the assistance of non-governmental organisations including universities and international organizations to assist, as long as there is a local investigator present.

# Question 29

Research should be carried out to serve the benefit of local patients and communities; not just the researcher. Inherent risks should be calculated and considered prior to the initiation of research. The population in which research is being carried out should be informed of any risk that may occur. They should also be informed about any results of the research results on an ongoing basis. An ethics committee should be consulted prior to research beginning. The committee should not just be comprised of researchers, but experts on ethics as well as members of affected communities. Agreement can then be made about appropriate practices balanced with the best scientific methodology for carrying out research.

Data should be de-identified if it is linked on some way to the patient. This includes medical record information, routine surveillance data and specimens. A policy should exist on the storage of specimens and for what purpose they can be used.